,

Rocard-F 77

Composition:

  • Rosuvastatin Calcium equivalent to Rosuvastatin 10 mg

  • Fenofibrate IP 67.5 mg
    Therapeutic Class:

  • Statin + Fibrate Combination
    Schedule: Schedule H (Prescription Only)

Rocard-F 77 is a synergistic lipid-lowering combination of Rosuvastatin, a potent statin, and Fenofibrate, a fibrate that targets triglyceride metabolism. This dual-action therapy is specially designed for patients with mixed dyslipidemia—those having elevated LDL-C, total cholesterol, and triglycerides (TG), particularly in the presence of low HDL-C.

This combination improves overall lipid profile, reduces cardiovascular risk, and is highly beneficial in patients with atherogenic dyslipidemia, diabetes mellitus, or metabolic syndrome.

Usage of Rocard-F 77

Rocard-F 77 is indicated in the treatment of:

  • Mixed dyslipidemia (elevated LDL-C + high TG + low HDL-C)

  • Severe hypertriglyceridemia

  • Atherogenic dyslipidemia in type 2 diabetes or metabolic syndrome

  • Residual cardiovascular risk in statin monotherapy non-responders

  • Cardiovascular prevention in high-risk patients (secondary prevention)


Mechanism of Action

🩺 Rosuvastatin (10 mg)

  • Inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis

  • Lowers LDL-C, total cholesterol, and ApoB

  • Modestly increases HDL-C

  • Has anti-inflammatory and plaque-stabilizing properties

🧬 Fenofibrate (67.5 mg)

  • Activates PPAR-α (peroxisome proliferator-activated receptor alpha)

  • Enhances lipolysis and clearance of TG-rich particles

  • Significantly lowers triglycerides and VLDL, increases HDL-C

  • Improves insulin sensitivity and endothelial function


Common Side Effects

  • Myalgia, muscle cramps

  • Headache or dizziness

  • Elevated liver enzymes (transaminases)

  • GI disturbances (nausea, abdominal pain)

  • Rare: Myopathy, rhabdomyolysis (in predisposed individuals)


Precautions

  • Avoid in active liver disease or persistent elevations of hepatic transaminases

  • Use cautiously in renal impairment; monitor renal function

  • Avoid in patients with gallbladder disease

  • Monitor CPK levels if muscle pain or weakness occurs

  • Avoid excessive alcohol intake


Drug Interactions

  • Statins + Fibrates: Risk of myopathy increases—especially with gemfibrozil (fenofibrate is safer)

  • Cyclosporine: Increases rosuvastatin exposure

  • Warfarin: Fenofibrate may potentiate anticoagulant effect—monitor INR

  • Avoid concurrent use with other hepatotoxic or myotoxic agents


Dosage and Administration

  • One tablet once daily, preferably in the evening, with or without food

  • Monitor lipid levels, liver enzymes, and renal function periodically

  • Ensure baseline CPK and LFTs before initiation


Storage

  • Store in a cool, dry place below 25°C

  • Protect from light and moisture

  • Keep out of reach of children


Patient Counseling Points

  • Report unexplained muscle pain, tenderness, or weakness

  • Adhere to low-fat, heart-healthy diet alongside therapy

  • Avoid grapefruit juice and alcohol overuse

  • Periodic blood tests are needed to monitor safety and efficacy

  • Safe use during pregnancy and lactation is not established; contraindicated

Review My Order

0

Subtotal